TW200806301A - Combination therapy of (2R,Z)-2-amino-2-cyclohexyl-N-(5-(1-methyl-1H-pyrazol-4-YL)-1-OXO-2,6-dihydro-1H-[1,2]diazepino[4,5,6-CD]indol-8-YL)acetamide - Google Patents

Combination therapy of (2R,Z)-2-amino-2-cyclohexyl-N-(5-(1-methyl-1H-pyrazol-4-YL)-1-OXO-2,6-dihydro-1H-[1,2]diazepino[4,5,6-CD]indol-8-YL)acetamide

Info

Publication number
TW200806301A
TW200806301A TW096111825A TW96111825A TW200806301A TW 200806301 A TW200806301 A TW 200806301A TW 096111825 A TW096111825 A TW 096111825A TW 96111825 A TW96111825 A TW 96111825A TW 200806301 A TW200806301 A TW 200806301A
Authority
TW
Taiwan
Prior art keywords
diazepino
indol
pyrazol
acetamide
dihydro
Prior art date
Application number
TW096111825A
Other languages
English (en)
Chinese (zh)
Inventor
Kenna Lynn Anderes
Alessandra Blasina
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200806301A publication Critical patent/TW200806301A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW096111825A 2006-04-04 2007-04-03 Combination therapy of (2R,Z)-2-amino-2-cyclohexyl-N-(5-(1-methyl-1H-pyrazol-4-YL)-1-OXO-2,6-dihydro-1H-[1,2]diazepino[4,5,6-CD]indol-8-YL)acetamide TW200806301A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78927606P 2006-04-04 2006-04-04

Publications (1)

Publication Number Publication Date
TW200806301A true TW200806301A (en) 2008-02-01

Family

ID=38421777

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096111825A TW200806301A (en) 2006-04-04 2007-04-03 Combination therapy of (2R,Z)-2-amino-2-cyclohexyl-N-(5-(1-methyl-1H-pyrazol-4-YL)-1-OXO-2,6-dihydro-1H-[1,2]diazepino[4,5,6-CD]indol-8-YL)acetamide

Country Status (14)

Country Link
US (1) US20090312280A1 (enExample)
EP (1) EP2007375A1 (enExample)
JP (1) JP2007277240A (enExample)
KR (1) KR20080100838A (enExample)
CN (1) CN101415417A (enExample)
AR (1) AR060284A1 (enExample)
AU (1) AU2007232279B2 (enExample)
BR (1) BRPI0709731A2 (enExample)
CA (1) CA2648371A1 (enExample)
IL (1) IL194340A0 (enExample)
MX (1) MX2008012791A (enExample)
RU (1) RU2409361C2 (enExample)
TW (1) TW200806301A (enExample)
WO (1) WO2007113671A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113436A1 (ja) * 2008-03-14 2009-09-17 国立大学法人千葉大学 Ｆｇｆｒ３遺伝子阻害剤の放射線照射併用による放射線の抗癌作用増強法および副作用軽減法
KR20100131457A (ko) * 2008-03-27 2010-12-15 다이호야쿠힌고교 가부시키가이샤 시티딘 유도체 및 카르보플라틴을 함유하는 항종양제
CN102612365B (zh) * 2009-04-11 2017-04-12 阵列生物制药公司 用于强化dna损伤剂的检查点激酶1抑制剂
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
TW201304778A (zh) 2010-11-16 2013-02-01 Array Biopharma Inc 檢查點激酶１抑制劑及ｗｅｅ１激酶抑制劑之組合
NO2797921T3 (enExample) 2011-12-31 2018-02-03
SG11201403538TA (en) 2011-12-31 2014-09-26 Beigene Ltd Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors
CA2928568A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
PL378372A1 (pl) * 2003-01-09 2006-04-03 Pfizer Inc. Tricykliczne związki jako inhibitory kinaz białkowych do wzmacniania skuteczności środków przeciwnowotworowych i radioterapii

Also Published As

Publication number Publication date
AU2007232279B2 (en) 2010-05-06
IL194340A0 (en) 2009-08-03
RU2409361C2 (ru) 2011-01-20
US20090312280A1 (en) 2009-12-17
AU2007232279A1 (en) 2007-10-11
AR060284A1 (es) 2008-06-04
WO2007113671A1 (en) 2007-10-11
CN101415417A (zh) 2009-04-22
RU2008139406A (ru) 2010-04-10
BRPI0709731A2 (pt) 2011-07-26
KR20080100838A (ko) 2008-11-19
MX2008012791A (es) 2008-10-15
JP2007277240A (ja) 2007-10-25
EP2007375A1 (en) 2008-12-31
CA2648371A1 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
TNSN08143A1 (en) 2-amino-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-ones
NZ595413A (en) Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
TW200503719A (en) Pyridino [1,2-a] pyrimidin-4-one compounds as anticancer agents
MX2009004516A (es) Metodos y terapias de combinacion para tratar enfermedad de alzheimer.
CL2008002139A1 (es) Compuestos dimeros derivados de pirrolo[2,1c][1.4]benzodiazepina- 5 -ona (tomaimicina), conjugado que los comprenden; procedimiento de preparacion de los conjugados; composicion farmaceutica que comprende a los compuestos o conjugados; y uso de los compuestos y de los conjugados en el tratamiento del cancer.
CL2008002687A1 (es) Uso de una combinacion farmaceutica de un compuesto derivado de tieno[3,2-d]pirimidina con un agente quimioterapeutico en el tratamiento de un trastorno hiperproliferativo; kit farmaceutico.
IL175714A0 (en) Quinazolinone compounds as anticancer agents
AR060284A1 (es) Terapia de combinacion de (2r,z)-2-amino-2-ciclohexil-n-(5-(1-metil-1h- pirazol- 4-il)-1- oxo- 2,6 dihidro-1h- [1,2] diazepino [4,5,6-cd] indol-8-il) acetamida
MX2010001218A (es) Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.
UA99459C2 (en) 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
IL212586A (en) Derivative 3 - (1, 3-benzoxazole-5-yl) pyrzolo [3, 4-d] pyrimidine-4-amine, a pharmaceutical preparation and the use of a drug derivative
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
TW200730525A (en) Therapeutic agents
AR074240A1 (es) Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci
CL2011000729A1 (es) Compuestos derivados de metanopirazolo[3,4-e][1,3]diazepin; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
AR082692A1 (es) Terapia de combinacion para el tratamiento del cancer, producto farmaceutico, equipo, kit
SV2008002856A (es) 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
UA105928C2 (uk) Солі метил-(r)-7-[3-аміно-4-(2,4,5-трифторфеніл)-бутирил]-3-трифторметил-5,6,7,8-тетрагідроімідазо[1,5-a]піразин-1-карбоксилату
MX2009005125A (es) Pirrolo[1,2-a]imidazoldiona efectiva en el tratamiento de neurotoxicidad periferica inducida por agentes quimioterapeuticos.
PL1718651T3 (pl) Pochodne 7H-pirolopirymidyny
WO2006076598A3 (en) Bicyclic heterocycles as cannabinoid receptor modulators
MX2008002272A (es) Compuestos de ciclopropilo y composiciones para suministrar agentes activos.